More than 80% of patients diagnosed with primary cutaneous melanoma
are without clinical evidence of metastatic disease at the time of diagnosis.
A novel, less-intensive monitoring schedule for patients with localized primary cutaneous melanoma
appears to reduce follow-up visits without affecting the rate of detection of new primary or recurrent melanomas, in an analysis of data from an inception cohort of 3,081 patients.
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
A search for primary cutaneous melanoma
at the time of presentation was negative.
Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma
CD44v3 levels in primary cutaneous melanoma
are predictive of prognosis: assessment by the use of tissue microarray.
In patients diagnosed with invasive primary cutaneous melanoma
, a detailed patient history is crucial, and a thorough examination of the skin and lymph nodes should be performed to help determine the extent of clinical spread of the disease.
When individuals with black skin acquire primary cutaneous melanoma
, the palms, soles, mucous membranes, and nailfolds are sites of predilection.
Although most melanoma recurrences from primary cutaneous melanoma
occur within 10 years of initial diagnosis (and the majority within 3 years), (2,3) "late" metastases, those that occur after 10 years of quiescence, have a reported incidence ranging from 0.
Our Melastatin(TM) gene research suggests that by examining the biology of cancer via gene expression, rather than a tumor's thickness, clinicians may have an additional data point in determining the prognosis of patients with primary cutaneous melanoma
tumors, the most deadly skin cancer," said Michael Kauffman, M.
Kashani-Sabet and associates tested this hypothesis in a retrospective study involving tissue specimens from 345 patients with primary cutaneous melanoma
Sentinel lymph node biopsy confers a survival benefit in patients with primary cutaneous melanoma
, according to preliminary results of a 5-year study.